GEN Exclusives

More »

GEN News Highlights

More »
Oct 19, 2007

Cold Spring Harbor Laboratories Suspends Dr. James Watson

  • The Cold Spring Harbor Laboratory (CSHL) board of trustees suspended the administrative responsibilities of chancellor James D. Watson, Ph.D. The action was taken in response to remarks attributed to Dr. Watson in the October 14 edition of The Sunday Times in the U.K., according to the board.

    During the Times interview, Dr. Watson allegedly made statements that black Africans are less intelligent than other races.

    The Federation of American Scientists (FAS) subsequently issued a statement expressing outrage at Dr. Watson’s comments. “At a time when the scientific community is feeling threatened by political forces seeking to undermine its credibility, it is tragic that one of the icons of modern science has cast such dishonor on the profession,” the statement notes.

    “The scientific enterprise is based on the promotion and proof of new ideas through evidence, however controversial, but Dr. Watson chose to use his unique stature to promote personal prejudices that are racist, vicious, and unsupported by science.

    “While we honor the extraordinary contributions that Dr. Watson has made to science in the past, his comments show that he has lost his way. He has failed us in the worst possible way. It is a sad and revolting way to end a remarkable career.”

    What is your opinion on CSHL's suspension of Dr. James Watson's administrative responsibilities in response to his alleged racist comments published in the October 14 edition of The Sunday Times in the U.K.? Blog about it on our website.


GEN Jobs powered by connects you directly to employers in pharma, biotech, and the life sciences. View 40 to 50 fresh job postings daily or search for employment opportunities including those in R&D, clinical research, QA/QC, biomanufacturing, and regulatory affairs.
More »

Be sure to take the GEN Poll

Easing Restrictions for Terminal Patients

Should the Federal Government Pass a “Right to Try” Bill Allowing Terminally Ill Patients Access to Experimental Medicines?

More »